Glad to share a case on HFpEF diagnosis and management including forxiga to a group of doctors along with esteemed speakers Dato Dr Azmee from IJN, Datuk Dr Akmal from Gleneagles KL & Dr Yew from Mahkota Melaka!
It was a great 1 & a half hour session with great food as well.
Key take home points are SGLT2i is the only class of medication from the 4 pillars to get class 1 indication for treatment of HFpEF at ESC guideline, no attenuation on effect of Forxiga across EF.
Hope to share more in the future.
1 thought on “Breakthrough in HFpEF: Key Takeaways from AstraZeneca’s Forxiga Discussion”
Comments are closed.